Monica Roy

Apr 9, 2024 | clinicalleader.com | Monica Roy

In this segment from Clinical Leader's Solutions Expo: EDC Showcase, Jan Breemans, Senior Director of Global Solutions at Signant Health, presents novel applications for EDC in modern trial designs. Watch the full presentation to learn how the SmartSignals Unified Platform can enhance data capture and trial management, simplifying the process for users.

Feb 13, 2024 | clinicalleader.com | Monica Roy |Helen Greta |Cenduit IRT

CLINICAL TRIAL TECHNOLOGYQuick Tips And Hot Takes For Selecting Clinical Trial TechnologyAvoid inefficient decision-making that keeps key downstream activities in limbo and select a new clinical trial technology efficiently with this technology selection guide. Why Aren’t More Sites Moving To eSource? In this segment, TF Pharma's Robert Goldman talks about different views of what eSource is and how, in some instances, this clinical trial technology doesn’t save any time over using paper.

Jan 22, 2024 | clinicalleader.com | Monica Roy

By Monica Roy, consultant “Swirl” connotes numerous meetings, multiple revisits of information, absence of a decision-making framework, and, ultimately, inefficient decision-making that keeps key downstream activities in limbo. No stranger to swirl is the act of selecting a new clinical trial technology and vendor. Avoid swirl and select a new clinical trial technology efficiently with this clinical trial technology selection guide.

Nov 15, 2023 | clinicalleader.com | Dan Schell |Monica Roy |Kerry Leyden

Bayer Launches Investigator-Sponsored Collaborative StudiesBayer added three Phase 3 trials to its MOONRAKER clinical development program for the study of Kerendia (finerenone) as a potential treatment for heart failure. Overall, the goal for the program is to enroll 15,000 participants.

Sep 25, 2023 | clinicalleader.com | Monica Roy

Guest Column | September 25, 2023 By Monica Roy, consultant The constantly shifting pharmaceutical landscape frequently leads pharma company senior management teams to shift their clinical development strategies in response. These clin dev shifts in turn affect study teams’ operational activities. Some study teams nimbly pivot while others fall further behind their study timeline. Why is this so?